drugset / Trial / NCT00657410

Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura

NCT00657410 ↗

Phase 3 Completed 150 enrolled GIMEMA Foundation
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs, such as prednisone and dexamethasone, may change the immune system and be an effective treatment for primary immune thrombocytopenic purpura. It is not yet known which drug is more effective in treating primary immune thrombocytopenic purpura. PURPOSE: This randomized phase III trial is studying high-dose dexamethasone to see how well it works compared to standard-dose prednisone in treating patients with newly diagnosed, previously untreated primary immune thrombocytopenic purpura.

Timeline

Start
2008-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg Oral
Subject Prednisone Other / unclassified 1 mg/kg Oral

Indications

No indication recorded.